NCT03541239 (KONDI-immun) is a NA clinical trial of Single Cuff Tourniquet 8000 in Ischemia Reperfusion Injury, sponsored by University of Aarhus.

Who is sponsoring NCT03541239?

NCT03541239 is sponsored by University of Aarhus.

What drugs are being tested in NCT03541239?

Interventions in NCT03541239: Single Cuff Tourniquet 8000.

What condition does NCT03541239 study?

NCT03541239 studies Ischemia Reperfusion Injury, Ischaemia Reperfusion Injury.

Is NCT03541239 still recruiting?

NCT03541239 is currently completed. Last updated 22 March 2019.

Last reviewed 2019-03-22 · How we verify

NCT03541239: KONDI-immun

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Modulation by Ischemic Pre-conditioning in Healthy Individuals: Intracellular Signalling in Regulatory Cells

Completed NA Last updated 22 March 2019

What this trial tests

NA trial testing Single Cuff Tourniquet 8000 in Ischemia Reperfusion Injury in 19 participants. Completed in 19 July 2016.

Timeline

31 March 2016

Primary endpoint
19 July 2016

19 July 2016

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	19
Start date	31 March 2016
Primary completion	19 July 2016
Estimated completion	19 July 2016
Sites	1 location across Denmark

Drugs / interventions tested

Single Cuff Tourniquet 8000

Conditions studied

Ischemia Reperfusion Injury — all drugs for Ischemia Reperfusion Injury →
Ischaemia Reperfusion Injury — all drugs for Ischaemia Reperfusion Injury →

Sponsor

University of Aarhus

Who can join

18 and older, male only, with Ischemia Reperfusion Injury or Ischaemia Reperfusion Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate how phosphorylation of STAT3, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) reacts to remote ischemic conditioning (rIC) in healthy humans, which could point to mechanisms by which rIC may protect against ischemia-reperfusion injury (IRI), and if rIC affects immune reactivity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Early Immunological Effects of Ischemia-Reperfusion Injury: No Modulation by Ischemic Preconditioning in a Randomised Crossover Trial in Healthy Humans.
Lange TH, Eijken M, Baan C, Petersen MS, et al · · 2019 · cited 4× · PMID 31200465 · DOI 10.3390/ijms20122877

Verify or expand the search:

Other recruiting trials for Ischemia Reperfusion Injury

Currently open trials in the same condition.

NCT05004610 — Hypertonic Lactate After Cardiac Arrest · Phase 2 · recruiting
NCT05992259 — Auricular Vagus Stimulation and STEMI · NA · recruiting
NCT05430620 — Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys · Phase 3 · recruiting
NCT04750616 — NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial · Phase 2 · recruiting
NCT04005469 — Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation · Phase 1, PHASE2 · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03541239 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 22 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing